StockNews.com downgraded shares of SCYNEXIS (NASDAQ:SCYX – Free Report) from a hold rating to a sell rating in a research note issued to investors on Monday.
SCYNEXIS Stock Performance
Shares of SCYX opened at $1.73 on Monday. The firm has a market cap of $65.36 million, a PE ratio of 0.85 and a beta of 1.52. SCYNEXIS has a 52-week low of $1.35 and a 52-week high of $3.87. The business’s 50 day moving average price is $2.00 and its two-hundred day moving average price is $1.88.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.11). The company had revenue of $0.74 million for the quarter. SCYNEXIS had a negative net margin of 366.09% and a negative return on equity of 57.41%. Research analysts predict that SCYNEXIS will post -0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On SCYNEXIS
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Read More
- Five stocks we like better than SCYNEXIS
- 3 REITs to Buy and Hold for the Long Term
- Deere Rebounds on Earnings Beat, But Uphill Battle Remains
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Mutual Funds vs Hedge Funds: What’s the Difference?
- P/E Ratio Calculation: How to Assess Stocks
- 3 Beaten-Down Tech Stocks That Shouldn’t Be Overlooked
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.